HRP20221414T1 - Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph - Google Patents
Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph Download PDFInfo
- Publication number
- HRP20221414T1 HRP20221414T1 HRP20221414TT HRP20221414T HRP20221414T1 HR P20221414 T1 HRP20221414 T1 HR P20221414T1 HR P20221414T T HRP20221414T T HR P20221414TT HR P20221414 T HRP20221414 T HR P20221414T HR P20221414 T1 HRP20221414 T1 HR P20221414T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- iia
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541370P | 2017-08-04 | 2017-08-04 | |
| PCT/US2018/044619 WO2019028034A1 (en) | 2017-08-04 | 2018-07-31 | Antifungal agents with enhanced activity in acidic ph |
| EP18755632.9A EP3661503B1 (en) | 2017-08-04 | 2018-07-31 | Antifungal agents with enhanced activity in acidic ph |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221414T1 true HRP20221414T1 (hr) | 2023-01-20 |
Family
ID=63209698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221414TT HRP20221414T1 (hr) | 2017-08-04 | 2018-07-31 | Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11534433B2 (https=) |
| EP (3) | EP4732902A2 (https=) |
| JP (1) | JP7214714B2 (https=) |
| KR (1) | KR102807716B1 (https=) |
| CN (2) | CN111093655A (https=) |
| AU (2) | AU2018309718B2 (https=) |
| BR (1) | BR112020002290A2 (https=) |
| CA (1) | CA3071940A1 (https=) |
| CY (1) | CY1125690T1 (https=) |
| DK (1) | DK3661503T3 (https=) |
| EA (1) | EA202090445A1 (https=) |
| ES (1) | ES2932658T3 (https=) |
| FI (1) | FI3661503T3 (https=) |
| HR (1) | HRP20221414T1 (https=) |
| HU (1) | HUE060508T2 (https=) |
| LT (1) | LT3661503T (https=) |
| MA (1) | MA49751B1 (https=) |
| MD (1) | MD3661503T2 (https=) |
| MX (1) | MX2020001399A (https=) |
| PL (1) | PL3661503T3 (https=) |
| PT (1) | PT3661503T (https=) |
| RS (1) | RS63746B1 (https=) |
| SI (1) | SI3661503T1 (https=) |
| SM (1) | SMT202200461T1 (https=) |
| TW (1) | TWI805600B (https=) |
| WO (1) | WO2019028034A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021016876A2 (pt) * | 2019-02-27 | 2021-11-03 | Scynexis Inc | Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto |
| AU2020276595B2 (en) * | 2019-05-16 | 2025-12-04 | Scynexis, Inc. | Antifungal Agents for Candida Auris Decolonization |
| WO2022140646A1 (en) * | 2020-12-26 | 2022-06-30 | Mycovia Pharmaceuticals, Inc | Dosing regimen for oteseconazole |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756472A (en) | 1996-01-31 | 1998-05-26 | Merck & Co., Inc. | Antifungal agent obtained from hormonema |
| JP5245057B2 (ja) | 2006-04-03 | 2013-07-24 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗真菌剤 |
| WO2010019204A1 (en) | 2008-08-12 | 2010-02-18 | Merck Sharp & Dohme Corp. | Antifungal agents |
| KR101686075B1 (ko) * | 2008-08-12 | 2016-12-13 | 싸이넥시스, 인크. | 항균제 |
| HRP20220544T1 (hr) | 2015-01-19 | 2022-08-05 | Scynexis, Inc. | Nove soli i polimorfi scy-078 |
| MA49889A (fr) * | 2017-04-10 | 2020-06-24 | Scynexis Inc | Agents antifongiques utilisés en association |
-
2018
- 2018-07-31 KR KR1020207005972A patent/KR102807716B1/ko active Active
- 2018-07-31 BR BR112020002290-0A patent/BR112020002290A2/pt not_active Application Discontinuation
- 2018-07-31 US US16/636,230 patent/US11534433B2/en active Active
- 2018-07-31 CA CA3071940A patent/CA3071940A1/en active Pending
- 2018-07-31 SI SI201830810T patent/SI3661503T1/sl unknown
- 2018-07-31 LT LTEPPCT/US2018/044619T patent/LT3661503T/lt unknown
- 2018-07-31 ES ES18755632T patent/ES2932658T3/es active Active
- 2018-07-31 SM SM20220461T patent/SMT202200461T1/it unknown
- 2018-07-31 EA EA202090445A patent/EA202090445A1/ru unknown
- 2018-07-31 RS RS20221058A patent/RS63746B1/sr unknown
- 2018-07-31 HR HRP20221414TT patent/HRP20221414T1/hr unknown
- 2018-07-31 AU AU2018309718A patent/AU2018309718B2/en active Active
- 2018-07-31 DK DK18755632.9T patent/DK3661503T3/da active
- 2018-07-31 PL PL18755632.9T patent/PL3661503T3/pl unknown
- 2018-07-31 JP JP2020505869A patent/JP7214714B2/ja active Active
- 2018-07-31 EP EP25222120.5A patent/EP4732902A2/en active Pending
- 2018-07-31 PT PT187556329T patent/PT3661503T/pt unknown
- 2018-07-31 MD MDE20200607T patent/MD3661503T2/ro not_active IP Right Cessation
- 2018-07-31 WO PCT/US2018/044619 patent/WO2019028034A1/en not_active Ceased
- 2018-07-31 EP EP18755632.9A patent/EP3661503B1/en not_active Revoked
- 2018-07-31 MA MA49751A patent/MA49751B1/fr unknown
- 2018-07-31 CN CN201880059398.2A patent/CN111093655A/zh active Pending
- 2018-07-31 MX MX2020001399A patent/MX2020001399A/es unknown
- 2018-07-31 CN CN202410653474.XA patent/CN118542868A/zh active Pending
- 2018-07-31 FI FIEP18755632.9T patent/FI3661503T3/fi active
- 2018-07-31 EP EP22193944.0A patent/EP4169514B1/en active Active
- 2018-07-31 HU HUE18755632A patent/HUE060508T2/hu unknown
- 2018-08-03 TW TW107127013A patent/TWI805600B/zh active
-
2022
- 2022-11-18 US US17/990,656 patent/US20230364067A1/en not_active Abandoned
- 2022-12-06 CY CY20221100767T patent/CY1125690T1/el unknown
-
2024
- 2024-10-21 AU AU2024227501A patent/AU2024227501A1/en active Pending
- 2024-12-03 US US18/967,641 patent/US20260000656A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231276T1 (hr) | Inhibitor egfr-a za liječenje raka | |
| HRP20221414T1 (hr) | Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph | |
| MX2024002425A (es) | Compuestos tricíclicos sustituidos como inhibidores de parp y uso de estos. | |
| HRP20210648T1 (hr) | Amid-supstituirani derivati piridiniltriazola i njihova uporaba | |
| FI3593817T3 (fi) | Koostumus käytettäväksi likinäköisyyden ehkäisyssä tai vähentämisessä | |
| IL305910B1 (en) | Oral dosage formulation of {[ 5-(3- (chlorophenyl)- 3-hydroxypyridine-2- carbonyl] amino} acetic acid | |
| JP2014516942A5 (https=) | ||
| HRP20161674T1 (hr) | 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE | |
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| JP2018529742A5 (https=) | ||
| US20110028510A1 (en) | Compositions, Methods, and Kits for Treating Influenza Viral Infections | |
| HRP20230935T1 (hr) | Postupci za liječenje i profilaksu hiv-a i aids-a | |
| JP2014511393A5 (https=) | ||
| Horiguchi et al. | Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT1A partial agonism | |
| HRP20251001T1 (hr) | Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije | |
| ME02474B (me) | Terapijski režimi | |
| JP2020100627A (ja) | １５−ｈｅｐｅを含む組成物及びそれを使用する方法 | |
| FI3897646T3 (fi) | Masitentaani keuhkovaltimoverenpainetaudin hoitoon | |
| IL270394B (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine | |
| CA2657590A1 (en) | Treatment of excess sebum production | |
| JP2020529999A5 (https=) | ||
| Yang et al. | Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer | |
| CA2660939A1 (en) | Pharmaceutical compositions for the treatment of fungal infections | |
| HRP20231448T1 (hr) | Primjena delgocitiniba za liječenje kroničnog ekcema ruku | |
| CR20190203A (es) | Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso |